(Q54478410)

English

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

0 references

Stewart McCallum

object named as

Stewart McCallum

2

0 references

author name string

Geoffrey I Shapiro

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

Laurel M Adams

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

Laurie Sherman

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

Steve Weller

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

Suzanne Swann

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

Harold Keer

7

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

Dale Miles

8

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

Thomas Müller

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

Patricia Lorusso

10

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

publication date

6 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

31

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

742-750

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

https://scigraph.springernature.com/pub.10.1007/s10637-012-9881-z

0 references

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Epithelial-mesenchymal transitions in tumour progression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

HGF/SF-met signaling in the control of branching morphogenesis and invasion

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Met, metastasis, motility and more

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Expression of c-met is a strong independent prognostic factor in breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Invasive growth: a MET-driven genetic programme for cancer and stem cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Hypoxia signalling in cancer and approaches to enforce tumour regression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Drug-target residence time and its implications for lead optimization

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9881-Z

21 January 2018

Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23054208

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23054208

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23054208

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23054208

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9881-Z

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23054208

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54478410&oldid=2143821862"